Free Trial

908 Devices Q4 2022 Earnings Report

908 Devices logo
$2.06 +0.12 (+6.19%)
(As of 12/20/2024 05:16 PM ET)

908 Devices EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.22
Beat/Miss
Missed by -$0.09
One Year Ago EPS
-$0.12

908 Devices Revenue Results

Actual Revenue
$11.60 million
Expected Revenue
$11.43 million
Beat/Miss
Beat by +$170.00 thousand
YoY Revenue Growth
-26.60%

908 Devices Announcement Details

Quarter
Q4 2022
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Cackling Kamala hates this company (Ad)

Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.

Before that happens, you need to see the details here.

908 Devices Earnings Headlines

908 Devices, Getinge enter Maven integration collaboration
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
Boston firm to shift manufacturing to North Carolina
See More 908 Devices Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 908 Devices? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 908 Devices and other key companies, straight to your email.

About 908 Devices

908 Devices (NASDAQ:MASS), a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

View 908 Devices Profile

More Earnings Resources from MarketBeat

Upcoming Earnings